ArticleImmunologic research2025
Spon2 knockdown suppresses the phenotype of house dust mite-induced allergic asthma in mice and cells.
Article in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic asthma is a chronic inflammatory disease of the airways. The objective of this study was to identify potential therapeutic targets for allergic asthma through RNA sequencing (RNA-seq) and experimental analyses. Allergic asthma models, both in cells and mice, were induced using house dust mite (HDM) treatment. RNA-seq analysis of lung tissues from HDM-induced allergic asthma mice and control mice was performed to identify differentially expressed genes (DEGs), and functional enrichment analysis of DEGs was performed. Spon2 knockdown was achieved via siRNA transfection and adeno-associated virus transduction. Bronchoalveolar lavage fluid (BALF) from mice was analyzed using cytology, ELISA for cytokines, and Giemsa staining. Lung tissues underwent HE staining, immunohistochemical staining, and Masson staining. Key gene expression levels were monitored in cellular and mouse models using real-time quantitative PCR and western blotting. RNA-seq and histological analysis of the HDM-induced allergic asthma mouse model revealed increased macrophage infiltration and upregulation of Spon2 in the lung tissues of mice with allergic asthma. Compared with the HDM-induced group, Spon2 knockdown led to decreased levels of inflammatory cytokines in the cellular model and, in the mouse model, it relieved HDM-caused histopathological alterations in mouse lungs, reduced collagen fiber deposition, lowered HDM-specific IgE expression in serum, and mitigated the HDM-induced increase in CD80 expression in lung tissues, total cell counts, and cytokine levels (IL-13, TNF-α, IFN-γ, IL-4, IL-5, IL-10) in BALF. Spon2 plays a role in the progression of HDM-induced allergic asthma and may be a potential therapeutic target worthy of further in vivo investigation.
Indexed as
Identifiers
40691739What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.